Nurix Therapeutics (NRIX) – Analysts’ Recent Ratings Updates

A number of research firms have changed their ratings and price targets for Nurix Therapeutics (NASDAQ: NRIX):

• 8/10/2026 – Nurix Therapeutics had its price target raised by Royal Bank Of Canada from $33.00 to $36.00. They now have an “outperform” rating on the stock.
• 8/8/2026 – Nurix Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 8/4/2026 – Nurix Therapeutics had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $34.00 price target on the stock.
• 7/28/2026 – Nurix Therapeutics had its price target raised by Morgan Stanley from $36.00 to $38.00. They now have an “overweight” rating on the stock.
• 7/22/2026 – Nurix Therapeutics had its price target raised by UBS Group AG from $23.00 to $31.00. They now have a “buy” rating on the stock.
• 7/17/2026 – Nurix Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/13/2026 – Nurix Therapeutics had its price target raised by Mizuho from $30.00 to $34.00. They now have an “outperform” rating on the stock.
• 7/12/2026 – Nurix Therapeutics was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 7/10/2026 – Nurix Therapeutics had its price target raised by Truist Financial Corporation from $32.00 to $34.00. They now have a “buy” rating on the stock.
• 7/10/2026 – Nurix Therapeutics had its price target raised by HC Wainwright from $32.00 to $34.00. They now have a “buy” rating on the stock.
• 7/10/2026 – Nurix Therapeutics had its price target raised by Stifel Nicolaus from $34.00 to $40.00. They now have a “buy” rating on the stock.
• 7/10/2026 – Nurix Therapeutics had its price target raised by Royal Bank Of Canada from $30.00 to $33.00. They now have an “outperform” rating on the stock.
• 7/10/2026 – Nurix Therapeutics had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $34.00 price target on the stock.
• 7/10/2026 – Nurix Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $32.00 price target on the stock.
• 6/29/2026 – Nurix Therapeutics is now covered by Oppenheimer Holdings, Inc.. They set an “outperform” rating and a $28.00 price target on the stock.
• 6/18/2026 – Nurix Therapeutics had its price target raised by Robert W. Baird from $26.00 to $33.00. They now have an “outperform” rating on the stock.
• 6/15/2026 – Nurix Therapeutics had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $34.00 price target on the stock.

Insiders Place Their Bets

In other Nurix Therapeutics news, insider Gwenn Hansen sold 4,356 shares of the business’s stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $25.00, for a total value of $108,900.00. Following the transaction, the insider owned 117,227 shares of the company’s stock, valued at approximately $2,930,675. The trade was a 3.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Houte Hans Van sold 4,761 shares of the business’s stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $24.36, for a total transaction of $115,977.96. Following the completion of the transaction, the chief financial officer directly owned 40,166 shares in the company, valued at $978,443.76. This trade represents a 10.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 25,314 shares of company stock worth $589,361 over the last quarter. 6.70% of the stock is currently owned by corporate insiders.

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.